Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 Sep 26

PMID 26404644

Citations 10

Authors

Ying-Li Lin

Shi-Liang Gui

Hong Guo

Jian-Guo Ma

Wen-Ping Li

Affiliations

Soon will be listed here.

Abstract

Background: Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.

Material And Methods: Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.

Results: PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.

Conclusions: PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.

Citing Articles

Ubiquitin ligase NEDD4 promotes the proliferation of hepatocellular carcinoma cells through targeting PCDH17 protein for ubiquitination and degradation.

Liu Z, Hu Q, Hu B, Cao K, Xu T, Hou T J Biol Chem. 2023; 300(1):105593.

PMID: 38145746 PMC: 10826327. DOI: 10.1016/j.jbc.2023.105593.

PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.

Chang Q, Sun J, Zhao S, Li L, Zhang N, Yan L Aging (Albany NY). 2023; 15(23):13753-13775.

PMID: 38048211 PMC: 10756125. DOI: 10.18632/aging.205261.

PCGF6/MAX/KDM5D facilitates MAZ/CDK4 axis expression and pRCC progression by hypomethylation of the DNA promoter.

Zhu M, Zhang R, Zhang H, Qu C, Zhang X, Ren L Epigenetics Chromatin. 2023; 16(1):9.

PMID: 36890610 PMC: 9996882. DOI: 10.1186/s13072-023-00483-w.

Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.

Koudonas A, Papaioannou M, Kampantais S, Anastasiadis A, Hatzimouratidis K, Dimitriadis G Medicine (Baltimore). 2022; 101(28):e29599.

PMID: 35838992 PMC: 11132415. DOI: 10.1097/MD.0000000000029599.

Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy.

Zhang Y, Niu J, Wu H, Si X, Zhang S, Li D Anal Cell Pathol (Amst). 2021; 2021:6692811.

PMID: 34194957 PMC: 8203385. DOI: 10.1155/2021/6692811.

References

van der Heijden A . The role of methylation in urological tumours. Arch Esp Urol. 2013; 66(5):432-9. View

Costa V, Henrique R, Danielsen S, Eknaes M, Patricio P, Morais A . TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics. 2011; 6(9):1120-30. DOI: 10.4161/epi.6.9.16376. View

Lin Y, Wang Y, Ma J, Li W . Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. J Exp Clin Cancer Res. 2015; 33:68. PMC: 4237820. DOI: 10.1186/s13046-014-0068-7. View

Lessi F, Mazzanti C, Tomei S, Di Cristofano C, Minervini A, Menicagli M . VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma. Med Oncol. 2014; 31(3):840. DOI: 10.1007/s12032-014-0840-8. View

Hu X, Sui X, Li L, Huang X, Rong R, Su X . Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J Pathol. 2012; 229(1):62-73. DOI: 10.1002/path.4093. View

Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S . Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics. 2013; 5(1):87-94. DOI: 10.2217/epi.12.68. View

Rydzanicz M, Wrzesinski T, Bluyssen H, Wesoly J . Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett. 2013; 341(2):111-26. DOI: 10.1016/j.canlet.2013.08.006. View

Keefe S, Nathanson K, Rathmell W . The molecular biology of renal cell carcinoma. Semin Oncol. 2013; 40(4):421-8. DOI: 10.1053/j.seminoncol.2013.05.006. View

Ahmad S, Arjumand W, Seth A, Saini A, Sultana S . Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol. 2011; 33(2):395-402. DOI: 10.1007/s13277-011-0235-9. View

10.

Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R . Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013; 108(1):131-8. PMC: 3553529. DOI: 10.1038/bjc.2012.537. View

11.

Xiao W, Wang J, Li H, Guan W, Xia D, Yu G . Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression. J Urol. 2013; 190(1):291-301. DOI: 10.1016/j.juro.2013.01.098. View

12.

Lo C, Huang W, Chao H, Lin K, Jen Y . Novel application of stereotactic ablative radiotherapy using CyberKnife for early-stage renal cell carcinoma in patients with pre-existing chronic kidney disease: Initial clinical experiences. Oncol Lett. 2014; 8(1):355-360. PMC: 4063570. DOI: 10.3892/ol.2014.2129. View

13.

Cairns P . Renal cell carcinoma. Cancer Biomark. 2011; 9(1-6):461-73. PMC: 3308682. DOI: 10.3233/CBM-2011-0176. View

14.

Pichler M, Hutterer G, Chromecki T, Jesche J, Kampel-Kettner K, Groselj-Strele A . Comparison of the 2002 and 2010 TNM classification systems regarding outcome prediction in clear cell and papillary renal cell carcinoma. Histopathology. 2012; 62(2):237-46. DOI: 10.1111/his.12001. View

15.

Chen W, Maniatis T . Clustered protocadherins. Development. 2013; 140(16):3297-302. PMC: 3737714. DOI: 10.1242/dev.090621. View

16.

Koukoura O, Spandidos D, Daponte A, Sifakis S . DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Mol Med Rep. 2014; 10(1):3-9. PMC: 4068729. DOI: 10.3892/mmr.2014.2221. View

17.

Kim S, Yasuda S, Tanaka H, Yamagata K, Kim H . Non-clustered protocadherin. Cell Adh Migr. 2010; 5(2):97-105. PMC: 3084973. DOI: 10.4161/cam.5.2.14374. View

18.

Ramakrishnan S, Pili R . Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J. 2013; 19(4):333-40. PMC: 3766322. DOI: 10.1097/PPO.0b013e3182a09e07. View

19.

Gyparaki M, Basdra E, Papavassiliou A . DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med (Berl). 2013; 91(11):1249-56. DOI: 10.1007/s00109-013-1088-z. View

20.

Rogenhofer S, Kahl P, Holzapfel S, von Ruecker A, Mueller S, Ellinger J . Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res. 2012; 32(3):879-86. View